Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Australia Breast Cancer Tissue Bank Resource Report Resource Website |
Australia Breast Cancer Tissue Bank (RRID:SCR_000926) | ABCTB | biomaterial supply resource, material resource | A tissue bank which houses and supplies cancerous tissue for use by the research community. Along with tissue, the bank collects clinical history, lifestyle factors, breast pathology, treatment information, and follow up information. | cancer, tissue bank, breast, tissue, human, clinical history, treatment information, pathology | Cancer | National Health and Medical Research Council of Australia ; National Breast Cancer Foundation ; Cancer Institute of NSW |
THIS RESOURCE IS NO LONGER IN SERVICE | nlx_54620 | SCR_000926 | 2026-02-17 09:59:33 | 0 | |||||||
|
JISTIC Resource Report Resource Website 1+ mentions |
JISTIC (RRID:SCR_003482) | JISTIC | software resource | Software tool for analyzing datasets of genome-wide copy number variation to identify driver aberrations in cancer. | copy number variation, candidate gene, gene |
is listed by: OMICtools has parent organization: Columbia University; New York; USA |
Cancer | PMID:20398270 | Free, Public | OMICS_02297 | SCR_003482 | 2026-02-14 02:00:28 | 2 | ||||||
|
Merck Resource Report Resource Website 10000+ mentions |
Merck (RRID:SCR_001287) | Merck | commercial organization | An American pharmaceutical company aiming to make a difference in the lives of people globally through their medicines, vaccines, biologic therapies and animal health products. | pharmaceutical, merck sharp & dohme corp, merck sharp and dohme corp, merck sharp and dohme, merck sharp & dohme corp., msd, medicine, endocrinology, neuroscience, oncology, respiratory, immunology, vaccine, animal health, veterinary |
uses: Kaggle uses: Tableau Desktop uses: FluoroFinder is affiliated with: European Federation of Pharmaceutical Industries and Associations is related to: eTRIKS is related to: OncoTrack is related to: European Lead Factory is related to: GetReal is related to: Investigator Databank is related to: Kinetics for Drug Discovery is related to: MIP-DILI is related to: ORBITO is related to: PharmaCog is related to: Asian Cancer Research Group is related to: Open PHACTS is related to: Collaboratory of AIDS Researchers for Eradciation (CARE) is parent organization of: MEDINA Foundation is parent organization of: Asian Cancer Research Group is parent organization of: Asia Training Consortium |
Diabetes, Cancer, Cardiovascular disease, Infectious disease | Crossref funder ID: 100004334, grid.417993.1, Wikidata: Q247489, ISNI: 0000 0001 2260 0793, nlx_152409 | https://ror.org/02891sr49 | SCR_001287 | Merck and Co., Merck and Co. Inc., Merck & Co. Inc., Merck & Co. | 2026-02-14 01:59:57 | 10277 | ||||||
|
SomaticCall Resource Report Resource Website |
SomaticCall (RRID:SCR_001196) | SomaticCall | software resource | Software program that finds single-base differences (substitutions) between sequence data from tumor and matched normal samples. It is designed to be highly stringent, so as to achieve a low false positive rate. It takes as input a BAM file for each sample, and produces as output a list of differences (somatic mutations). Note: This software package is no longer supported and information on this page is provided for archival purposes only. | somatic mutation, substitution, sequence, bam, mutation |
is listed by: OMICtools has parent organization: Broad Institute |
Tumor, Cancer, Normal | OMICS_02155 | SCR_001196 | 2026-02-14 02:00:01 | 0 | ||||||||
|
Foundation for the National Institutes of Health Resource Report Resource Website 1000+ mentions |
Foundation for the National Institutes of Health (RRID:SCR_004493) | FNIH | institution | A public charity whose mission is to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research and training. Its vision is Building Partnerships for Discovery and Innovation to Improve Health. The FNIH draws together the world''s foremost researchers and resources, pressing the frontier to advance critical discoveries. They are recognized as the number-one medical research charity in the countryleveraging support, and convening high level partnerships, for the greatest impact on the most urgent medical challenges we face today. Grants are awarded as part of a public-private partnership with the National Heart, Lung, and Blood Institute (NHLBI) on behalf of The Heart Truth in support of women''s heart health education and research. Funding for the Community Action Program is provided by the FNIH through donations from individuals and corporations including The Heart Truth partners Belk Department Stores, Diet Coke, and Swarovski. Successful biomedical research relies upon the knowledge, training and dedication of those who conduct it. Bringing multiple disciplines to bear on health challenges requires innovation and collaboration on the part of scientists. Foundation for NIH partnerships operate in a variety of ways and formats to recruit, train, empower and retain their next generation of researchers. From lectures and multi-week courses, to scholarships and awards through fellowships and residential training programs, their programs respond to the needs of scientists at every level and stage in their careers. | biomedical research |
is related to: Osteoarthritis Biomarkers Project (OABP) is parent organization of: Biomarkers Consortium is parent organization of: Observational Medical Outcomes Partnership is parent organization of: Accelerating Medicines Partnership Autoimmune Diseases of Rheumatoid Arthritis and Lupus is parent organization of: Accelerating Medicines Partnership - Alzheimers is parent organization of: Accelerating Medicines Partnership Type 2 Diabetes Knowledge Portal (AMP-T2D) is parent organization of: Genetic Association Information Network (GAIN) |
Type 1 diabetes, Type 2 diabetes, Diabetes, Metabolic disease, Alzheimer's disease, Schizophrenia, Prostate cancer, Demantia, Muscular dystrophy, Tuberculosis, HIV, Parkinson's disease, Osteoarthritis, Age-related eye disease, Visceral leishmaniasis, Undiagnosed disease, Cancer, Non-small cell lung cancer, Malaria, Systemic lupus erythematosus, COVID-19, Acute lymphoblastic leukemia | ISNI: 0000 0000 9836 9834, Wikidata: Q16837497, nlx_143768, Crossref funder ID: 100000009, grid.428807.1 | https://ror.org/00k86s890 | SCR_004493 | Foundation for NIH | 2026-02-14 02:00:44 | 1788 | ||||||
|
Capital Biosciences Resource Report Resource Website 1+ mentions |
Capital Biosciences (RRID:SCR_004879) | commercial organization | Biological products including Cell Immortalization Products, Clinically Defined Human Tissue, cDNA ORF Clones, Premade Adenoviruses, Purified Proteins, Viral Expression Systems and others as well as services like Custom Recombinant Adenovirus Production, Custom Recombinant Lentivirus Production, Protein Detection and Quantification and Stable Cell Line Production for academic and governmental research institutes, pharmaceutical and biotechnology industry. Capital Biosciences offers most types of human tissues, normal and diseased, with extensive clinical history and follow up information. Standard specimen format: Snap-frozen(flash-frozen), Formalin fixed and paraffin embedded (FFPE) tissues, Blood and blood products, Bone marrow, Total RNA, Genomic DNA, Total Proteins, Primary cell cultures, Viable frozen tissue. Tumor tissue samples include: Bladder cancer, Glioblastoma, Medulloblastoma, Breast Carcinoma, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck (H&N) Carcinoma, Hepatocellular Carcinoma (HCC), Hodgkin's lymphoma, Kidney, Renal Cell Carcinoma, Lung Cancer, Non-Small Cell (NCSLC), Lung Cancer, Small Cell (SCLC), Melanoma, Mesothelioma, non-Hodgkin's Lymphoma, Ovarian Adenocarcinoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer. | cell immortalization, clinical, tissue, cdna orf clone, premade adenovirus, purified protein, viral expression, recombinant adenovirus, recombinant lentivirus, protein, detection, quantification, cell line, disease, formalin fixed and paraffin embedded, frozen, tissue, blood, blood product, bone marrow, rna, dna, protein, cell culture, tumor tissue | is listed by: One Mind Biospecimen Bank Listing | Normal, Cancer, Tumor, Bladder cancer, Glioblastoma, Medulloblastoma, Breast Carcinoma, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Head Carcinoma, Neck Carcinoma, Hepatocellular Carcinoma, Hodgkin's lymphoma, Kidney, Renal Cell Carcinoma, Lung Cancer, Non-Small Cell, Lung Cancer, Small Cell, Melanoma, Mesothelioma, Non-Hodgkin's Lymphoma, Ovarian Adenocarcinoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer | nlx_85333 | http://www.capitalbiosciences.com/category/show/tissue-human-clinically-defined.html | SCR_004879 | Capital Biosciences: innovative solutions for life sciences, Capital Biosciences Inc. | 2026-02-14 02:00:46 | 2 | |||||||
|
Southeastern Brain Tumor Foundation Resource Report Resource Website |
Southeastern Brain Tumor Foundation (RRID:SCR_004768) | SBTF | institution | Founded in 1995, the Southeastern Brain Tumor Foundation (SBTF), a 501c3 not-for-profit charitable foundation, is devoted to improve the quality of life for brain tumor patients and their families. By offering information, education and support services, we aspire to instill hope, knowledge and comfort to all involved. The Southeastern Brain Tumor Foundation also raises funds for research and medical personnel so that a cure can be found. For over a decade, the SBTF has become a well-known fundraising entity supporting critical, cutting edge brain tumor research at major medical centers in the Southeast. Our annual Race for Research held in Atlanta, Georgia each summer, is our main fundraising event popular throughout Atlanta and the surrounding metropolitan area and has funded over $1.2 million dollars in research grants to leading researchers at major medical centers throughout the Southeast over the past decade. We are proud of our dedicated, all volunteer Board of Directors who meet monthly. Our Board is a diverse group comprised of individuals who''ve been touched by brain tumors in many different ways. Ranging from patients and family members to healthcare professionals; we are all committed to promoting the awareness of brain tumors in the community, communicating with patients and families and raising critical funds for research grants furthering advancements in the treatment of brain tumors. Our monthly support group, lead by a nurse practitioner, welcomes patients and their families to sit side by side with each other, share their experiences, communicate and receive support. As a neurosurgeon-scientist focused on the treatment of patients with brain tumors, I am committed to advancing the mission of SBTF forward in the fight against brain tumors. Our ability to serve the brain tumor community is dependent on each of you. Whether you support us with a financial donation in our fundraising efforts or with your time as a volunteer, each of you are a vital and integral part of our success and we thank you. | brain, tumor | Cancer, Brain cancer, Brain tumor | Crossref funder ID: 100003421, ISNI: 0000 0004 5902 7216, grid.481206.9, nlx_143897 | https://ror.org/01v0qv381 | SCR_004768 | 2026-02-14 02:01:01 | 0 | ||||||||
|
Terry Fox Foundation Resource Report Resource Website 1+ mentions |
Terry Fox Foundation (RRID:SCR_005873) | TFF | institution | The Terry Fox Foundation is responsible for supporting close to $20 million in discovery based research each year in Canada - all monies raised outside Canada must be distributed to (a) an institute approved by the Foundation and its advisors or (b) remitted to Canada. The Terry Fox Research Institute (TFRI) is a recipient of TFF funding for translational research. TFRI is an exciting new initiative whose goal is to translate rapidly today''s best science into better cancer treatment and diagnosis for all Canadians. The Institute will bring scientists and clinicians together across the country into a functionally integrated, geographically dispersed Institute with nodes in several provinces. Terry Fox was diagnosed with osteogenic sarcoma (bone cancer) in his right leg in 1977 and had his leg amputated 15 cm (six inches) above the knee. While in hospital, Terry was so overcome by the suffering of other cancer patients that he decided to run across Canada to raise money for cancer research. He called his journey the Marathon of Hope. Terry''s Marathon of Hope took place in 1980 with the simple objective of informing Canadians of the importance of finding a cure for cancer. With fierce determination, he ran an average of 42 kilometres (26 miles) every day for 143 days. Terry was forced to end his run on September 1, 1980 when the cancer spread to his lungs. By February 1, 1981, Terry''s dream of raising $1 for every Canadian was realized - the Terry Fox Marathon of Hope fund totaled $24.17 million. Terry died in June 1981. On May 26, 1988, The Terry Fox Run became a Trust, independent from the Canadian Cancer Society, and received tax-exempt charitable registration as a public foundation. In addition to our signature and long-standing National Terry Fox Run Day in September of each year, The Terry Fox Foundation is proud to include in its events portfolio The National School Run Day. The Foundation recognizes the duality of its mandate. Not only does it raise money for research, but it also continues to share the story of Terry Fox. The Terry Fox Foundation strives to maintain the heroic effort and integrity that Terry embodied. It is a grassroots organization that does not allow the Terry Fox name or likeness to be commercialized or conjoined with other worthy causes. To date, over $600 million has been raised worldwide for cancer research in Terry''s name. | research, cancer | is parent organization of: Terry Fox Research Institute | Cancer | ISNI: 0000 0004 5907 4557, Crossref funder ID: 501100002655, nlx_149429, grid.453650.1 | https://ror.org/05vd00053 | SCR_005873 | 2026-02-14 02:00:59 | 5 | |||||||
|
ACTREC - Advanced Centre for Treatment Research and Education in Cancer Resource Report Resource Website 1+ mentions |
ACTREC - Advanced Centre for Treatment Research and Education in Cancer (RRID:SCR_006021) | ACTREC | institution | The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the new state-of-the-art R&D satellite of the Tata Memorial Centre (TMC), which also includes under its umbrella the Tata Memorial Hospital (TMH), the largest cancer hospital in Asia. ACTREC has the mandate to function as a national centre for treatment, research and education in cancer. TMC is an autonomous grant-in-aid institution of the Department of Atomic Energy (DAE), Government of India. It is registered under the Societies Registration Act (1860) and the Bombay Public Trust Act (1950). Its Governing Council is headed by the Chairman, Atomic Energy Commission, Government of India. ACTREC comprises of 2 arms - one for basic research and another for clinical research. The basic research building was inaugurated in March 2002 at the new site of ACTREC in Kharghar, Navi Mumbai. In August 2002, the Cancer Research Institute (CRI) shifted in toto from its Parel campus in Mumbai to serve as the basic research arm of ACTREC. The clinical research arm of ACTREC comprising of the Clinical Research Centre (CRC) has become functional from March 2005. ACTREC also has a 50-bed hospital fully equipped with state-of-the-art diagnostic and therapeutic facilities. Research investigations at CRI currently focus on molecular mechanisms responsible for causation of major human cancers relevant to India. It is envisaged that in the future, ACTREC will play a greater role in drug development and emerging therapies for treatment and prevention of cancer. | cancer, basic research, clinical research, drug development, therapy, treatment, prevention, research, education | is parent organization of: HIstome: The Histone Infobase | Cancer | Crossref funder ID: 501100007179, ISNI: 0000 0004 1766 7522, grid.410869.2, nlx_151418 | https://ror.org/05b9pgt88 | SCR_006021 | Advanced Centre for Treatment Research and Education in Cancer | 2026-02-14 02:01:12 | 2 | ||||||
|
Longevity Foundation Resource Report Resource Website |
Longevity Foundation (RRID:SCR_006338) | Longevity Foundation | funding resource | Funding resource that supports research into A-T (Ataxia Telangiectasia) and other debilitating, degenerative diseases plaguing human kind, including cancer and neuro-degeneration associated with auto-immunity and aging. Researchers share their findings and collaborate with each other. The research must lead to practical, near-term treatments and cures to receive funds. The researchers have found treatments and cures that are the first of their kind in the world. Over $850,000 in direct research grants have been made. These grants have leveraged over $9 million in research resources contributed by partner institutions. We pay the research institutions for direct costs only. We pay no administrative, indirect, or overhead costs. | grant, research | Degenerative disease, Ataxia Telangiectasia, Neurodegeneration, Autoimmunity, Inflammation, Premature aging, Aging, Cancer | nlx_152041 | SCR_006338 | 2026-02-14 02:01:08 | 0 | |||||||||
|
CGARS Resource Report Resource Website |
CGARS (RRID:SCR_006404) | CGARS | software resource | Software package to dissect random from non-random patterns in copy number data and thereby to assess significantly enriched somatic copy number aberrations (SCNA) across a set of tumor specimens or cell lines. | genome, analysis |
is listed by: OMICtools has parent organization: University of Cologne; Cologne; Germany |
Cancer | PMID:24413525 | GNU General Public License, v3 or later | OMICS_02210 | SCR_006404 | CGARS: Cancer Genome Analysis by Rank Sums, Cancer Genome Analysis by Rank Sums | 2026-02-14 02:01:07 | 0 | |||||
|
Socrates Resource Report Resource Website 50+ mentions |
Socrates (RRID:SCR_006411) | Socrates | software resource | Software for detecting genomic rearrangements in tumors that utilizes only split-read data. It features single nucleotide resolution, high sensitivity, and high specificity in simulated data. It takes advantage of parallelism for efficient use of resources. | genomic rearrangement |
is listed by: OMICtools has parent organization: Walter and Eliza Hall Institute of Medical Research; Victoria; Australia |
Tumor, Cancer | PMID:24389656 | GNU General Public License, v3, Socrates makes use of external libraries that are licensed under, Apache License, v2, MIT License, Acknowledgement requested | OMICS_02200 | SCR_006411 | Socrates: Identification of genomic rearrangements in tumour genomes by re-aligning soft clipped reads, SOft Clip re-alignment To idEntify Structural variants, Socrates - SOft Clip re-alignment To idEntify Structural variants | 2026-02-14 02:01:17 | 53 | |||||
|
AbsCN-seq Resource Report Resource Website 1+ mentions |
AbsCN-seq (RRID:SCR_006409) | AbsCN-seq | software resource | Statistical software to estimate tumor purity, ploidy and absolute copy numbers from next generation sequencing data. | r, statistics, purity, ploidy, absolute copy number, next-generation sequencing |
is listed by: OMICtools has parent organization: University of California at San Diego; California; USA |
Tumor, Cancer | PMID:24389661 | Free, Public | OMICS_02202 | SCR_006409 | 2026-02-14 02:01:18 | 6 | ||||||
|
Hybrigenics Resource Report Resource Website 10+ mentions |
Hybrigenics (RRID:SCR_003822) | commercial organization | A bio-pharmaceutical company with a focus on research and development of new targets & therapies against proliferative diseases. Its current development program is based on inecalcitol, a vitamin D receptor agonist being studied in three potential indications: * alone in chronic lymphocytic leukaemia * in combination with imatinib in chronic myeloid leukaemia * in prostate cancer, for use with current standards of care Hybrigenics'' research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics Services, a Hybrigenics subsidiary, markets very specialized scientific services to researchers in all areas of life sciences who want to identify, validate and inhibit protein interactions in animal, plant or microbiological cells. | enzyme, proteomic, protein interaction network, protein interaction | is related to: AgedBrainSYSBIO | Lymphocytic leukaemia, Myeloid leukaemia, Prostate cancer, Cancer | nlx_158127 | SCR_003822 | 2026-02-14 02:00:52 | 16 | |||||||||
|
Amorfix Resource Report Resource Website 1+ mentions |
Amorfix (RRID:SCR_003783) | AMF | commercial organization | Product development company focused on therapeutic products and diagnostic devices targeting misfolded protein diseases. On July, 2015 the company name was changed to ProMIS Neurosciences, Inc. | diagnostic, therapy, alzheimer, protein, misfolded protein disease | Alzheimer's disease, Amyotrophic Lateral Sclerosis, Cancer | Crossref funder ID: 100007611, nlx_158072, grid.422608.a | https://ror.org/045rtab03 | SCR_003783 | Amorfix Life Science, Amorfix Life Sciences Ltd., Amorfix Life Sciences, ProMIS Neurosciences | 2026-02-14 02:00:53 | 2 | |||||||
|
ChemoCentryx Resource Report Resource Website 10+ mentions |
ChemoCentryx (RRID:SCR_003976) | commercial organization | A biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Each drug candidate is a small molecule designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025. | biopharmaceutical, oral administration, medicine, small molecule, chemokine, chemo-attractant receptor, clinical, drug, oral drug | is related to: Kidney Health Initiative | Autoimmune disease, Inflammatory disorder, Cancer | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_158383, grid.452218.8, ISNI: 0000 0004 0408 7502 | https://ror.org/04gp12571 | SCR_003976 | ChemoCentryx Inc, ChemoCentryx Inc. | 2026-02-14 02:00:55 | 43 | ||||||
|
C. R. Bard Resource Report Resource Website 1+ mentions |
C. R. Bard (RRID:SCR_003975) | BARD, BCR | commercial organization | A multinational developer, manufacturer, and marketer of medical technologies specializing in the manufacture of vascular, urology, oncology and surgical specialty products. BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs. Bard is perhaps best known for having introduced the Foley catheter. (Adapted from Wikipedia) | medical equipment, vascular, urology, oncology, surgical, medical technology, medical, clinical | is related to: Kidney Health Initiative | Cancer | nlx_158382 | SCR_003975 | C. R. Bard Inc., C.R. Bard Inc., C. R. Bard Inc, CR Bard, C.R. Bard Inc, C.R. Bard, CR Bard Inc. | 2026-02-14 02:00:38 | 2 | |||||||
|
Centre for Genomics and Oncological Research Resource Report Resource Website |
Centre for Genomics and Oncological Research (RRID:SCR_003920) | GENYO | institution | Center for excellence research in genomic medicine, focusing on the comprehensive study and understanding of the genetic basis of human diseases in general, placing special emphasis on cancer and its genetic disorders related to inheritance. GENYO was created as a multidisciplinary research space, where different professionals from the healthcare, university and business areas interact, making it possible to generate new systems to diagnose, prevent and treat diseases based on the joint and coordinated application of first-rate knowledge in the different areas of genetics. The center is the benchmark center of the Andalusian Program for Research in Clinical Genetics and Genomic Medicine, a program which, together with those of Cell Therapy and Regenerative Medicine, and Nanomedicine have the main objective of supporting and fostering translational research in Advanced Therapies. The activities performed within these three research programs are developed in coordination with the Andalusian Initiative for Advanced Therapies (IATA), an initiative of the Andalusian Government promoted by the Regional Ministries of Health and Innovation, Science and Enterprise. | genomic medicine, genomic, oncology, pharmacogenomics, inheritance, genetics |
is related to: PRECISESADS has parent organization: University of Granada; Granada; Spain has parent organization: Progress and Health Foundation; Seville; Spain is parent organization of: PRECISESADS |
Cancer, Genetic disorder | grid.470860.d, Crossref funder ID: 501100007321, nlx_158281, ISNI: 0000 0004 4677 7069 | https://ror.org/04hr99439 | SCR_003920 | Pfizer-University of Granada-Junta de Andaluc??a Centre for Genomics and Oncological Research (GENYO), Pfizer-University of Granada-Junta de Andaluc??a Centre for Genomics and Oncological Research | 2026-02-14 02:00:33 | 0 | ||||||
|
Institute of Cancer Research Resource Report Resource Website 10+ mentions |
Institute of Cancer Research (RRID:SCR_003912) | ICR | institution | Academic cancer research center, a postgrad college, and a charity in the United Kingdom that is making discoveries that defeat cancer. With their partners The Royal Marsden NHS Foundation Trust they form the largest comprehensive cancer center in Europe and perform high quality and original basic research and translational studies, with the aim of developing better treatments for the benefit of cancer patients worldwide. The ICR offers comprehensive, modern facilities for research and studentships supported by the Wellcome Trust, MRC, CRUK and EPSRC and the ICR''s own resources which are awarded on a competitive basis. The ICR offers postgraduate research degrees (MPhil, PhD and MD (Res)) and a modular postgraduate taught degree in oncology aimed at clinicians undertaking specialist training in the field of Clinical or Medical Oncology leading to a Postgraduate Certificate, Postgraduate Diploma or MSc in Oncology. | clinical, medical, oncology |
is related to: PREDECT has parent organization: University of London; London; United Kingdom is parent organization of: FLIGHT is parent organization of: MoKCa- Mutations of Kinases in Cancer |
Cancer | nlx_158259, grid.18886.3f, Wikidata: Q6039999, ISNI: 0000 0001 1271 4623 | https://ror.org/043jzw605 | SCR_003912 | The Institute of Cancer Research | 2026-02-14 02:00:38 | 12 | ||||||
|
Orion Resource Report Resource Website 10+ mentions |
Orion (RRID:SCR_003911) | Orion | commercial organization | A globally operating Finnish developer, manufacturer and marketer of human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. They are continuously developing new drugs and treatment methods. Pharmaceutical RD focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs. | pharmaceutical, drug, diagnostic test, diagnostic, central nervous system, drug, oncology, critical care, pulmonary, central nervous system drug, pulmonary drug, cancer, veterinary drug, medicine, clinical, hygiene monitoring |
is related to: MIP-DILI is related to: NEWMEDS is related to: ORBITO is related to: PREDECT |
Cancer, Asthma, Alzheimer's disease, Parkinson's disease, Breast cancer, Prostate cancer | nlx_158257 | SCR_003911 | Orion Corporation, Orion Pharma | 2026-02-14 02:00:53 | 34 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the SPARC SAWG Resources search. From here you can search through a compilation of resources used by SPARC SAWG and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that SPARC SAWG has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on SPARC SAWG then you can log in from here to get additional features in SPARC SAWG such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into SPARC SAWG you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
